SAMEEN BOZAI: Open Payments
NPI 1508519240 · VIENNA, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,045 in 50 payments from 11 companies in 2025. Trend: 2023 $4,253 · 2024 $1,314 · 2025 $1,045
Food & beverage: $1,045
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $325 |
| Otsuka America Pharmaceutical, Inc. | 12 | $284 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $178 |
| AstraZeneca Pharmaceuticals LP | 4 | $79 |
| Novo Nordisk Inc | 3 | $64 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $25 |
| Optinose US, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Exact Sciences Corporation | 1 | $19 |
Products named: REXULTI, CAPLYTA, VRAYLAR, QULIPTA, Wegovy, FARXIGA, BREZTRI, JARDIANCE.
Industry payments across VA — which companies pay providers there.
